Skip to main content
SpringerLink
Log in

Serum soluble urokinase-type plasminogen activator receptor and interferon-γ-induced protein 10 levels correlate with significant fibrosis in chronic hepatitis B

  • original article
  • Published:
Wiener klinische Wochenschrift Aims and scope Submit manuscript

Summary

Background

Hepatitis B virus (HBV) presents an important public health problem. Liver biopsy is currently the gold standard for assessing the degree of intrahepatic inflammation and for staging liver fibrosis. However, the value of liver biopsies is limited by sampling errors, understaging and interobserver variability in interpretation. There is, therefore, a need to identify novel, non-invasive serologic biomarkers for the development of new predictive models of fibrosis.

Methods

We enrolled patients with chronic hepatitis B infection (CHB) and examined the relationships between serum soluble urokinase plasminogen activator receptor (suPAR) and interferon-induced protein-10 (IP-10), and the results of liver biopsies. Healthy volunteers with normal aminotransferase levels and negative serological results for HBV, hepatitis C virus and human immunodeficiency virus were recruited as controls.

Results

Mean platelet volume, serum suPAR and IP-10 were significantly elevated in patients with CHB compared with controls. Median serum suPAR and IP-10 levels were significantly higher in patients with liver fibrosis compared with patients with mild fibrosis. There was no significant difference in mean platelet volume or aspartate aminotransferase-to-platelet ratio index scores between patients with mild and significant fibrosis.

Conclusion

suPAR and IP-10 were able to distinguish between significant and mild fibrosis with good sensitivity and specificity, and may thus represent useful biomarkers for identifying patients with significant fibrosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Liver EAFTSOT. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167–85.

    Article  Google Scholar 

  2. Karlmark KR, Wasmuth HE, Trautwein C, Tacke F. Chemokine-directed immune cell infiltration in acute and chronic liver disease. Expert Rev Gastroenterol Hepatol. 2008;2(2):233–42.

    Article  CAS  PubMed  Google Scholar 

  3. Fontana RJ, Goodman ZD, Dienstag JL, Bonkovsky HL, Naishadham D, Sterling RK, et al. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology. 2008;47(3):789–98.

    Article  CAS  PubMed  Google Scholar 

  4. Castera L. Hepatitis B: are non-invasive markers of liver fibrosis reliable? Liver Int. 2014;34Suppl. 1:91–6.

    Article  CAS  PubMed  Google Scholar 

  5. Donadello K, Scolletta S, Covajes C, Vincent J-L. suPAR as a prognostic biomarker in sepsis. BMC Med. 2012;10(1):2.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Zimmermann H, Reuken P, Koch A, Bartneck M, Adams D, Trautwein C, et al. Soluble urokinase plasminogen activator receptor is compartmentally regulated in decompensated cirrhosis and indicates immune activation and short-term mortality. J Intern Med. 2013;274(1):86–100.

    Article  CAS  PubMed  Google Scholar 

  7. Berres M-L, Schlosser B, Berg T, Trautwein C, Wasmuth HE. Soluble urokinase plasminogen activator receptor is associated with progressive liver fibrosis in hepatitis C infection. J Clin Gastroenterol. 2012;46(4):334–8.

    Article  CAS  PubMed  Google Scholar 

  8. Xu Z, Liu Y, Liu L, Li X, Bai S, Rong Y, et al. Association of interferon-gamma induced protein 10 promoter polymorphisms with the disease progression of hepatitis B virus infection in Chinese Han population. PLoS One. 2013;8(9):e72799.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Ceylan B, Fincanci M, Yardimci C, Eren G, Tozalgan U, Muderrisoglu C, et al. Can mean platelet volume determine the severity of liver fibrosis or inflammation in patients with chronic hepatitis B? Eur J Gastroenterol Hepatol. 2013;25(5):606–12.

    Article  CAS  PubMed  Google Scholar 

  10. Karagoz E, Ulcay A, Tanoglu A, Kara M, Turhan V, Erdem H, et al. Clinical usefulness of mean platelet volume and red blood cell distribution width to platelet ratio for predicting the severity of hepatic fibrosis in chronic hepatitis B virus patients. Eur J Gastroenterol Hepatol. 2014;26(12):1320–4.

    CAS  PubMed  Google Scholar 

  11. Zeremski M, Dimova R, Brown Q, Jacobson IM, Markatou M, Talal AH. Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infection. J Infect Dis. 2009;200(11):1774–80.

    Article  CAS  PubMed  Google Scholar 

  12. Ceylan B, Mete B, Fincanci M, Aslan T, Akkoyunlu Y, Ozgunes N, et al. A new model using platelet indices to predict liver fibrosis in patients with chronic hepatitis B infection. Wien Klin Wochenschr. 2013;125(15–16):453–60.

    Article  CAS  PubMed  Google Scholar 

  13. Baranova A, Lal P, Birerdinc A, Younossi ZM. Non-invasive markers for hepatic fibrosis. BMC Gastroenterol. 2011;11:91. doi:10.1186/1471-230X-11-91.

    Article  PubMed Central  PubMed  Google Scholar 

  14. Li J, Gordon SC, Rupp LB, Zhang T, Boscarino JA, Vijayadeva V, et al. The validity of serum markers for fibrosis staging in chronic hepatitis B and C. J Viral Hepat. 2014;21(12):930–7.

    Article  CAS  PubMed  Google Scholar 

  15. Andersen ES, Ruhwald M, Moessner B, Christensen PB, Andersen O, Eugen-Olsen J, et al. Twelve potential fibrosis markers to differentiate mild liver fibrosis from cirrhosis in patients infected with chronic hepatitis C genotype 1. Eur J Clin Microbiol Infect Dis. 2011;30(6):761–6.

    Article  CAS  PubMed  Google Scholar 

  16. Zimmermann HW, Koch A, Seidler S, Trautwein C, Tacke F. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis. Liver Int. 2011;32(3):500–9.

    PubMed  Google Scholar 

  17. Fibbi G, D’Alessio S, Pucci M, Cerletti M, Del Rosso M. Growth factor-dependent proliferation and invasion of muscle satellite cells require the cell-associated fibrinolytic system. Biol Chem. 2002;383(1):127–36.

    Article  CAS  PubMed  Google Scholar 

  18. Koch A, Zimmermann HW, Gassler N, Jochum C, Weiskirchen R, Bruensing J, et al. Clinical relevance and cellular source of elevated soluble urokinase plasminogen activator receptor (suPAR) in acute liver failure. Liver Int. 2014;34(9):1330–9. doi:10.1111/liv.12512.

    Article  CAS  PubMed  Google Scholar 

  19. Sjöwall C, Martinsson K, Cardell K, Ekstedt M, Kechagias S. Soluble urokinase plasminogen activator receptor levels are associated with severity of fibrosis in nonalcoholic fatty liver disease. Transl Res. 2015;165(6):658–66. doi:10.1016/j.trsl.2014.09.007.

    Article  PubMed  Google Scholar 

  20. You CR, Park S-H, Jeong SW, Woo HY, Bae SH, Choi JY, et al. Serum IP-10 levels correlate with the severity of liver histopathology in patients infected with genotype-1 HCV. Gut liver. 2011;5(4):506–12.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Lee IC, Lin CH, Huang YH, Huo TI, Su CW, Hou MC, et al. IL28B polymorphism correlates with active hepatitis in patients with HBeAg-negative chronic hepatitis B. PLoS One. 2013;8(2):e58071.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Wang J, Zhao J-H, Wang P-P, Xiang G-J. Expression of CXC chemokine IP-10 in patients with chronic hepatitis B. Hepatobiliary Pancreat Dis Int. 2008;7(1):45–50.

    CAS  PubMed  Google Scholar 

  23. Mihm S, Schweyer S, Ramadori G. Expression of the chemokine IP-10 correlates with the accumulation of hepatic IFN-γ and IL-18 mRNA in chronic hepatitis C but not in hepatitis B. J Med Virol. 2003;70(4):562–70.

    Article  CAS  PubMed  Google Scholar 

  24. Harvey CE. Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. J Leukocyte Biol. 2003;74(3):360–9.

    Article  CAS  PubMed  Google Scholar 

  25. Xiao G, Yang J, Yan L. Comparison of Diagnostic accuracy of APRI and FIB-4 for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis. Hepatology. 2015;61(1):292–302.

    Article  PubMed  Google Scholar 

  26. Assal A, Mackie D, Cooper CL. Transient elastography, APRI, and ultrasound have minimal utility in chronic low-replicative hepatitis B infection. Eur J Gastroenterol Hepatol. 2014;26(9):1010–4.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Infectious Diseases and Clinical Microbiology, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey

    Dilek Yıldız Sevgi MD, Alper Gündüz MD, Nuray Uzun MD &  İlyas Dökmetaş

  2. Department of Clinical Microbiology, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey

    Banu Bayraktar, Alper Togay MD & Emin Bulut MD

  3. Department of Pathology, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey

    Banu Yılmaz Özgüven MD

Authors
  1. Dilek Yıldız Sevgi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Banu Bayraktar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alper Gündüz MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Banu Yılmaz Özgüven MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alper Togay MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Emin Bulut MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nuray Uzun MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. İlyas Dökmetaş
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dilek Yıldız Sevgi MD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sevgi, D., Bayraktar, B., Gündüz, A. et al. Serum soluble urokinase-type plasminogen activator receptor and interferon-γ-induced protein 10 levels correlate with significant fibrosis in chronic hepatitis B. Wien Klin Wochenschr 128, 28–33 (2016). https://doi.org/10.1007/s00508-015-0886-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00508-015-0886-4

Keywords

Search

Navigation